Search Results - "антиаритмические препараты"

1

Academic Journal

Эсмолол В Терапии Нарушений Ритма Сердца: Результаты Клинического Исследования

Authors: Г.М, Тулабоева, Х.М., Сагатова, Ю.Ш, Талипова, Н.М., Абдукадирова, А.А., Хусанов

Source: World of Medicine : Journal of Biomedical Sciences; Vol. 2 No. 7 (2025): World of Medicine : Journal of Biomedical Sciences; 5-9 ; 2960-9356

Subject Terms: синусовая тахикардия, наджелудочковые тахикардии, фибрилляция предсердий, антиаритмические препараты, эсмолол

File Description: application/pdf

Relation: https://wom.semanticjournals.org/index.php/biomed/article/view/484/418; https://wom.semanticjournals.org/index.php/biomed/article/view/484

Availability: https://wom.semanticjournals.org/index.php/biomed/article/view/484

View record from BASE

2

Academic Journal

Clinical and Psychopathological Features of Mental Disorders in Patients with Poisoning by Hypotensive and Antiarrhythmic Drugs as a Result of Suicidal Acts ; Клинико-психопатологические особенности психических расстройств у больных с отравлением гипотензивными и антиаритмическими препаратами в результате суицидальных действий

Authors: T. I. Dikaya, K. K. Ilyashenko, G. N. Sukhodolova, O. V. Zubareva, M. M. Potskhveriya, Т. И. Дикая, К. К. Ильяшенко, Г. Н. Суходолова, О. В. Зубарева, М. М. Поцхверия

Contributors: The study has no sponsorship, Исследование не имеет спонсорской поддержки

Source: Russian Sklifosovsky Journal "Emergency Medical Care"; Том 12, № 4 (2023); 607-613 ; Журнал им. Н.В. Склифосовского «Неотложная медицинская помощь»; Том 12, № 4 (2023); 607-613 ; 2541-8017 ; 2223-9022

Subject Terms: постсуицидальные состояния, hypotensive and antiarrhythmic drugs, mental disorders, post-suicidal states, гипотензивные и антиаритмические препараты, психические расстройства

File Description: application/pdf

Relation: https://www.jnmp.ru/jour/article/view/1724/1359; https://www.jnmp.ru/jour/article/view/1724/1419; Dieserud G, Loed M, Ekeberg O. Suicidal behavior in the municipality of Baerum, Norway: a 12-year prospective study of parasuicide and suicide. Suicidе Life Threat Behav. 2000;30(1):61–73. PMID:10782719; Лужников Е.А. (ред.) Медицинская токсикология : национальное руководство. Москва: ГЭОТАР-Медиа; 2012.; Уманский М.С., Зотов П.Б., Абатурова О.В., Жмуров В.А., Родяшин Е.В., Приленский А.Б. Суицид и сердечно-сосудистые заболевания: есть ли взаимосвязь? Суицидология. 2017;8(3):94–99.; Касимова Л.Н., Святогор М.В., Втюрина М.В. Анализ суицидальных попыток путем самоотравления. Суицидология. 2011;2(1):54–55.; Приленский А.Б. Характер средств, выбранных пациентами для преднамеренного отравления с суицидальной целью (на примере Тюменской области). Научный форум. Сибирь. 2016;2(4):95–96.; Sorensen HT, Mellemkjaer L, Olsen JH. Risk of suicide in users of b-adrenoceptor blockers, calcium channel blockers and angiotensinconverting enzyme inhibitors. Br J Clin Pharmacol. 2001;52(3):313–318. PMID: 11560564 doi:10.1046/j.0306-5251.2001.01442.x; Белова М.В., Ильяшенко К.К. Острые отравления препаратами, действующими преимущественно на сердечно-сосудистую систему. Токсикологический вестник. 2016;(5):31–35. doi:10.36946/0869-7922-2016-5-31-35; Баланова Ю.А., Шальнова С.А., Имаева А.Э., Капустина А.В., Муромцева Г.А., Евстифеева С.Е. и др. Распространенность артериальной гипертонии, охват лечением и его эффективность в Российской Федерации (данные наблюдательного исследования ЭССЕ-Р 2). Рациональная фармакотерапия в кардиологии. 2019;15(4):450–466. doi:10.20996/1819-6446-2019-15-4-450-466; Пахомова С.А., Деренок А.П., Кузьмина И.А. Аффективные расстройства в кардиологической практике. Бюллетень медицинских Интернет-конференций. 2015;5(2):138.; Нефедова Е.А. Динамика тревожных расстройств в соматическом стационаре. Бюллетень медицинских Интернет-конференций. 2014;4(3):166.; Челышева И.А., Бунина И.С., Герасимова Ю.А., Краснощекова Л.И. Особенности тревожно-депрессивных расстройств при осложнениях гипертонической болезни (инфаркте миокарда и ишемическом инсульте). Вестник Ивановской медицинской академии. 2012;17(4):23–26.; Зуева О.Н., Сморгов Л.М., Привалова М.А., Абакаров Ш.А. Проблемы постинсультной депрессии в раннем восстановительном периоде ишемического инсульта у больных пожилого возраста. Академический журнал Западной Сибири. 2014;10(3):60–61.; Лебедева Е.В., Симуткин Г.Г., Счастный Е.Д., Репин А.Н., Сергиенко Т.Н. Особенности тревожно-депрессивных расстройств и суицидального поведения у пациентов пожилого и старческого возраста с хронической ишемической болезнью сердца. Суицидология. 2014;5(2):69–76.; Смулевич А.Б. Депрессии при соматических и психических заболеваниях. Москва: МИА; 2007.; Войцех В.Ф. Клиническая суицидология. Москва: Миклош; 2008.; Амбрумова А.Г., Тихоненко В.А. Диагностика суицидального поведения: Методические рекомендации. Москва; 1980.; Васильев В.В., Смирнова Т.А., Баталова Н.П. Особенности пресуицидальных и постсуицидальных состояний у женщин. Медицинская психология в России : электронный научный журнал. 2010;(1). URL: http://www.medpsy.ru/mprj/archiv_global/2010_1_2/nomer/nomer10.php [Дата обращения 11 ноября 2023 года]; Васильев В.В., Сергеева Е.А. Проявления суицидального поведения у больных органическими психическими расстройствами. Сибирский вестник психиатрии и наркологии. 2018;1(98):62–67. doi:10.26617/1810-3111-2018-1(98)-62-67; Beghi M, Rosenbaum JF, Cerri C, Cornaggia CM. Risk factors for fatal and nonfatal repetition of suicide attempts: A literature review. Neuropsychiatr Dis Treat. 2013;9:1725–1736. PMID: 24235836 doi:10.2147/NDT.S40213; Olfson M, Blanco C, Wall M, Liu SM, Saha TD, Pickering RP, et al. National trends in suicide attempts among adults in the United States. JAMA Рsychiatry. 2017;74(11):1095–1103. PMID: 28903161 doi:10.1001/jamapsychiatry.2017.2582; https://www.jnmp.ru/jour/article/view/1724

Availability: https://www.jnmp.ru/jour/article/view/1724
https://doi.org/10.23934/2223-9022-2023-12-4-607-613

View record from BASE

3

Academic Journal

Chronic kidney disease and atrial fibrillation: approaches to the choice of antiarrhythmic therapy ; Хроническая болезнь почек и фибрилляция предсердий: подходы к выбору антиаритмической терапии

Authors: B. A. Tatarsky, N. V. Kazennova, Б. А. Татарский, Н. В. Казеннова

Source: Siberian Journal of Clinical and Experimental Medicine; Том 38, № 4 (2023); 20-28 ; Сибирский журнал клинической и экспериментальной медицины; Том 38, № 4 (2023); 20-28 ; 2713-265X ; 2713-2927

Subject Terms: гемодиализ, chronic kidney disease, antiarrhythmic drugs, proarrhythmia, hemodialysis, хроническая болезнь почек, антиаритмические препараты, проаритмия

File Description: application/pdf

Relation: https://www.sibjcem.ru/jour/article/view/2047/918; Dan G.A., Martinez-Rubio A., Agewall S., Boriani G., Borggrefe M., Gaita F. et al. Antiarrhythmic drugs–clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). Europace. 2018;20(5):731–732an. DOI:10.1093/europace/eux373.; Potpara T.S., Jokic V., Dagres N., Marin F., Prostran M.S., Blomstrom-Lundqvist C. et al. Cardiac arrhythmias in patients with chronic kidney disease: implications of renal failure for antiarrhythmic drug therapy. Curr. Med. Chem. 2016;23(19):2070–2083. DOI:10.2174/0929867323666160309114246.; Andò G., Capranzano P. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with chronic kidney disease: A systematic review and network meta-analysis. Int. J. Cardiol. 2017;231:162–169. DOI:10.1016/j.ijcard.2016.11.303.; Hill N.R., Fatoba S.T., Oke J.L., Hirst J.A., O’Callaghan C.A., Lasserson D.S. et al. Global prevalence of chronic kidney disease – A systematic review and meta-analysis. PLoS One. 2016;11(7):e0158765. DOI:10.1371/journal.pone.0158765.; Steinberg B.A., Kim S., Piccini J.P., Fonarow G.C., Lopes R.D., Thomas L. et al. Insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. Circulation. 2013;128(7):721–728. DOI:10.1161/CIRCULATIONAHA.113.002927.; Бойцов С.А., Лукьянов М.М., Якушин С.С., Марцевич С.Ю., Воробьев А.Н., Загребельный А.В. и др. Регистр кардиоваскулярных заболеваний (РЕКВАЗА): диагностика, сочетанная сердечно-сосудистая патология, сопутствующие заболевания и лечение в условиях реальной амбулаторно-поликлинической практики). Кардиоваскулярная Терапия и Профилактика. 2014;13(6):44–50.; Benjamin E.J., Blaha M.J., Chiuve S.E., Cushman M., Das S.R., Deo R. et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A report from the American Heart Association. Circulation. 2017;135(10):e146–e603. DOI:10.1161/CIR.0000000000000485.; Heine G., Brandenburg V. Anticoagulation, atrial fibrillation and chronic kidney disease – whose side are you on? Kidney International. 2017;91:771–786. DOI:10.1016/j.kint.2016.11.028.; Alonso A., Lopez F.L., Matsushita K., Loehr L.R., Agarwal S.K., Chen L.Y. et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011;123(25):2946–2953. DOI:10.1161/CIRCULATIONAHA.111.20982.; Guo Y., Wang H., Zhao X., Zhang Y., Zhang D., Ma J. et al. Sequential changes in renal function and the risk of stroke and death in patients with atrial fibrillation. Int. J. Cardiol. 2013;168(5):4678–4684. DOI:10.1016/j.ijcard.2013.07.179.; National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update. Am. J. Kidney Dis. 2012;60(5):850–886. DOI:10.1053/j.ajkd.2012.07.005.; Kirchhof P., Benussi S., Kotecha D., Ahlsson A., Atar D., Casadei B. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. Heart J. 2016;37(38):2893–2962. DOI:10.1093/eurheartj/ehw210.; Steffel J., Verhamme P., Potpara T.S., Albaladejo P., Antz M., Desteghe L. et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur. Heart J. 2018;39(16):1330–1393. DOI:10.1093/eurheartj/ehy136.; Turakhia M.P., Blankestijn P.J., Carrero J.J., Clase C.M., Deo R., Herzog C.A. et al. Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Eur. Heart J. 2018;39:2314–2325. DOI:10.1093/eurheartj/ehy060.; Boriani G., Savelieva I., Dan G.A., Deharo J.C., Ferro C., Israel C.W. et al. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace. 2015;17(8):1169–1196. DOI:10.1093/eurheartj/ehw210.; Kumar S., Lim E., Covic A., Verhamme P., Gale C.P., Camm A.J. et al. Anticoagulation in concomitant chronic kidney disease and atrial fibrillation. JACC. 2019;74(17):2204–2215. DOI:10.1016/j.jacc.2019.08.1031.; Szummer K., Evans M., Carrero J.J., Alehagen U., Dahlström U., Benson L. et al. Comparison of the chronic kidney disease epidemiology collaboration, the modification of diet in renal disease study and the Cockcroft–Gault equation in patients with heart failure. Open Heart. 2017;4:e000568. DOI:10.1136/openhrt-2016-000568.; Turakhia M.P., Blankestijn P.J., Carrero J.J., Clase C.M., Deo R., Herzog C.A. et al. Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Eur. Heart J. 2018;39(24):2314–2325. DOI:10.1093/eurheartj/ehy060.; January C.T., Wann L.S., Calkins H., Chen L.Y., Cigarroa J.E., Cleveland J.C. Jr. et al. Focused Update of the 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation. Circulation. 2019;140(2):e125–e151. DOI:10.1161/CIR.0000000000000665.; Wyse D.G., Waldo A.L., DiMarco J.P., Domanski M.J., Rosenberg Y., Schron E.B. et al. Atrial Fibrillation Follow-up Investigation of Rhythm Management Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med. 2002;347(23):1825– 1833. DOI:10.1056/NEJMoa021328.; Wyse D.G. Rate control vs rhythm control strategies in atrial fibrillation. Prog. Cardiovasc. Dis. 2005;48(2):125–138. DOI:10.1016/j.pcad.2005.06.008.; Ревишвили А.Ш., Рзаев Ф.Г, Горев М.В., Нардая Ш.Г.; Всероссийское научное общество специалистов по клинической электрофизиологии, аритмологии и кардиостимуляции, Российское кардиологическое общество, Ассоциация сердечно-сосудистых хирургов. Диагностика и лечение фибрилляции предсердий: Клинические рекомендации. М.: 2017.; Reinecke H., Nabauer M., Gerth A., Limbourg T., Treszl A., Engelbertz C. et al. Morbidity and treatment in patients with atrial fibrillation and chronic kidney disease. Kidney Int. 2015;87(1):200–209. DOI:10.1038/ki.2014.195.; Schmidt M., Daccarett M., Rittger H., Marschang H., Holzmann S., Jung Ph. et al. Renal dysfunction and atrial fibrillation recurrence following cardioversion. J. Cardiovasc. Electrophysiol. 2011;22(10):1092– 1098. DOI:10.1111/j.1540-8167.2011.02069.x.; Ullal A.J., Kaiser D.W., Fan J., Schmitt S.K., Than C.T., Winkelmayer W.C. et al. Safety and clinical outcomes of catheter ablation of atrial fibrillation in patients with chronic kidney disease. J. Cardiovasc. Electrophysiol. 2017;28(1):39–48. DOI:10.1111/jce.13118.; Li M., Liu T., Luo D., Li G. Systematic review and meta-analysis of chronic kidney disease as predictor of atrial fibrillation recurrence following catheter ablation. J. Cardiol. 2014;21(1):89–95. DOI:10.5603/CJ.a2013.0116.; Yanagisawa S., Inden Y., Kato H., Fujii A., Mizutani Y., Ito T. et al. Impaired renal function is associated with recurrence after cryoballoon catheter ablation for paroxysmal atrial fibrillation: a potential effect of non-pulmonary vein foci. J. Cardiol. 2017;69(1):3–10. DOI:10.1016/j.jjcc.2016.07.008.; Takahashi Y., Takahashi A., Kuwahara T., Okubo K., Fujino T., Takagi K. et al. Renal function after catheter ablation of atrial fibrillation. Circulation. 2011;124(22):2380–2387. DOI:10.1161/CIRCULATIONAHA.111.047266.; Van Gelder I.C., Groenveld H.F., Crijns H.J., Tuininga Y.S., Tijssen J.G., Alings A.M. et al. RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. N. Engl. J. Med. 2010;362(15):1363– 1373. DOI:10.1056/NEJMoa1001337.; Williams E.S., Thompson V.P., Chiswell K.E., Alexander J.H., White H.D., Ohman E.M. et al. Rate versus rhythm control and outcomes in patients with atrial fibrillation and chronic kidney disease: data from the GUSTO-III Trial. Cardiol. J. 2013;20(4):439–446. DOI:10.5603/CJ.2013.0104.; Weir M.A., Dixon S.N., Fleet J.L., Roberts M.A., Hackam D.G., Oliver M.J. et al. Beta-Blocker dialyzability and mortality in older patients receiving hemodialysis. J. Am. Soc. Nephrol. 2015;26(4):987–996. DOI:10.1681/ASN.2014040324.; https://www.sibjcem.ru/jour/article/view/2047

Availability: https://www.sibjcem.ru/jour/article/view/2047
https://doi.org/10.29001/2073-8552-2023-38-4-20-28

View record from BASE

4

Academic Journal

ПРОГНОСТИЧЕСКОЕ ЗНАЧЕНИЕ ДЕФИЦИТА МАГНИЯ СЫВОРОТКИ КРОВИ У ПАЦИЕНТОВ С НАРУШЕНИЯМИ РИТМА СЕРДЦА, ПРИНИМАЮЩИХ АНТИАРИТМИЧЕСКИЕ ПРЕПАРАТЫ III КЛАССА

Authors: L. V. Kalatsei, V. A. Snezhitskiy

Source: Žurnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta, Vol 20, Iss 4, Pp 380-386 (2022)

Subject Terms: магний, гипомагниемия, антиаритмические препараты iii класса, лекарственноиндуцированный синдром удлиненного интервала qt, желудочковые нарушения ритма, полиморфная желудочковая тахикардия, Medicine

File Description: electronic resource

Relation: http://journal-grsmu.by/index.php/ojs/article/view/2865; https://doaj.org/toc/2221-8785; https://doaj.org/toc/2413-0109

Access URL: https://doaj.org/article/8593f69ec1324286b6287bff695968c8

View record in DOAJ Full Text Finder

5

Academic Journal

УРОВЕНЬ ТЕСТОСТЕРОНА СЫВОРОТКИ КРОВИ КАК ПРЕДИКТОР ЛЕКАРСТВЕННО-ИНДУЦИРОВАННОГО УДЛИНЕНИЯ ИНТЕРВАЛА QT И ПОЛИМОРФНОЙ ЖЕЛУДОЧКОВОЙ ТАХИКАРДИИ У ПАЦИЕНТОВ МУЖСКОГО ПОЛА, ПРИНИМАЮЩИХ АНТИАРИТМИЧЕСКИЕ СРЕДСТВА III КЛАССА

Authors: L. V. Kalatsei, V. A. Snezhitskiy, V. R. Shulika

Source: Žurnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta, Vol 20, Iss 3, Pp 261-271 (2022)

Subject Terms: тестостерон, антиаритмические препараты iii класса, интервал qt, лекарственно-индуцированный синдром удлиненного интервала qt, полиморфная желудочковая тахикардия, электрокардиография, Medicine

File Description: electronic resource

Relation: http://journal-grsmu.by/index.php/ojs/article/view/2798; https://doaj.org/toc/2221-8785; https://doaj.org/toc/2413-0109

Access URL: https://doaj.org/article/03ff8aa4d80742cba96c0fba0894a15f

View record in DOAJ Full Text Finder

6

Academic Journal

Clinical and Psychological Features of Patients With Poisoning By Antihypertensive and Antiarrhythmic Drugs as a Result of Suicidal Actions ; Клинико-психологические особенности больных с отравлением гипотензивными и антиаритмическими препаратами в результате суицидальных действий

Authors: A. B. Kholmogorova, O. D. Pugovkina, M. I. Subotich, A. V. Komova, M. M. Potskhveria, G. N. Sukhodolova, А. Б. Холмогорова, О. Д. Пуговкина, М. И. Суботич, А. В. Комова, М. М. Поцхверия, Г. Н. Суходолова

Source: Russian Sklifosovsky Journal "Emergency Medical Care"; Том 11, № 4 (2022); 584-591 ; Журнал им. Н.В. Склифосовского «Неотложная медицинская помощь»; Том 11, № 4 (2022); 584-591 ; 2541-8017 ; 2223-9022

Subject Terms: профилактика, antihypertensive and antiarrhythmic drugs, risk factors, depressive disorders, suicidal behavior, prevention, гипотензивные и антиаритмические препараты, факторы риска, депрессивные расстройства, суицидальное поведение

File Description: application/pdf

Relation: https://www.jnmp.ru/jour/article/view/1515/1234; https://www.jnmp.ru/jour/article/view/1515/1253; Касимова Л.Н., Святогор М.В., Втюрина М.В. Анализ суицидальных попыток путем самоотравления. Суицидология. 2011;1:54–55.; Шикалова И.А., Лодягин А.Н., Барсукова И.М., Насибуллина А.Р., Каллойда Д.Ю. Анализ токсикологической ситуации по данным трех специализированных центров Российской Федерации. Неотложная медицинская помощь. Журнал им. Н.В. Склифосовского. 2019;8(4):373–378. https://doi.org/10.23934/2223-9022-2019-8-4-373378; Белова М.В., Ильяшенко К.К. Острые отравления препаратами, действующими преимущественно на сердечно-сосудистую систему. Токсикологический вестник. 2016;5:31–35. https://doi.org/10.36946/0869-7922-2016-5-31-35; Мягков А.Ю., Смирнова Е.Ю. Структура и динамика незавершенных самоубийств. Социологические исследования. 2007;3:89–96.; Ticehurst S, Carter GL, Clover KA, Whyte IM, Raymond J, Fryer J. Elderly patients with deliberate self-poisoning treated in an Australian general hospital. Int Psychogeriatr. 2002;14(1):97–105. PMID: 12094912 https://doi.org/10.1017/s1041610202008311; Sørensen HT, Mellemkjaer L, Olsen JH. Risk of suicide in users of b-adrenoceptor blockers, calcium channel blockers and angiotensin converting enzyme inhibitors. Br J Clin Pharmacol. 2001;52(3):313–318. PMID: 11560564 https://doi.org/10.1046/j.0306-5251.2001.01442.x; Potential under-recognised risk of harm from the use of propranolol. Healthcare Safety Investigation Branch. 2020. Available at: https://www.hsib.org.uk/investigations-and-reports/potential-under-recognised-risk-of-harm-from-the-use-of-propranolol/potential-underrecognised-risk-of-harm-from-the-use-of-propranolol/ [Accessed October14, 2022].; Пуговкина О.Д., Холмогорова А.Б., Поцхверия М.М., Суходолова Г. Н. Самоотравления гипотензивными препаратами: клиникопсихологические и социально-демографические факторы и общие подходы к профилактике. Неотложная медицинская помощь. Журнал им. Н.В. Склифосовского. 2021;10(4):719–727. https://doi.org/10.23934/2223-9022-2021-10-4-719-727; Алехин А.Н., Трифонова Е.А. Психологические факторы кардиометаболического риска: история и современное современное состояние проблемы. Артериальная гипертензия. 2012;18(4):278–291.; Kretchi IA, Owusu-Daaku FT, Danquah SA. Mental health in hypertension: assessing symptoms of anxiety, depression and stress on anti-hypertensive medication adherence. Int J Ment Health Syst. 2014;8:25. PMID: 24987456 https://doi.org/10.1186/1752-4458-8-25; Холмогорова А.Б., Суботич М.И., Корх М.П., Рахманина А.А., Быкова М.С. Дезадаптивные личностные черты и психопатологическая симптоматика у лиц с первой попыткой суицида и хроническим суицидальным поведением. Консультативная психология и психотерапия. 2020;28(1):63–86. https://doi.org/10.17759/cpp.2020280105; Холмогорова А.Б. Суицидальное поведение: теоретическая модель и практика помощи в когнитивно-бихевиоральной терапии. Консультативная психология и психотерапия. 2016;24(3):144–163. https://doi.org/10.17759/cpp.2016240309; https://www.jnmp.ru/jour/article/view/1515

Availability: https://www.jnmp.ru/jour/article/view/1515
https://doi.org/10.23934/2223-9022-202211-4-584-591

View record from BASE

7

Academic Journal

Particularitățile utilizării preparatelor antiaritmice la pacienții cu comorbidități cardiace

Authors: Catcov, C., Chişlaru, S., Rakovskaia, T.

Source: Sănătate Publică, Economie şi Management în Medicină 93-S (2) 241-245

Subject Terms: амиодарон, cardiac comorbidities, beta-adrenoblockers, бета-адреноблокаторы, amiodaronă, beta-adrenoblocante, сопутствующие заболевания сердца, comorbidități cardiace, antiarrhythmics, amiodarone, антиаритмические препараты, antiaritmice

File Description: application/pdf

Access URL: https://ibn.idsi.md/vizualizare_articol/171872

View record at OpenAIRE

8

Academic Journal

Wide QRS complex tachycardia: the underlying mechanisms, differential diagnosis and acute treatment

Source: Лекарства Украины; № 8(264) (2022); 22-32
Medicine of Ukraine; No. 8(264) (2022); 22-32
Ліки України; № 8(264) (2022); 22-32

Subject Terms: терапія, аберантне проведення, диагностика, антиаритмічні препарати, діагностика, катетерная абляция, antiarrhythmic drugs, wide QRS complex, catheter ablation, diagnostics, механизмы, широкие комплексы QRS, суправентрикулярна тахікардія, mechanisms, therapy, терапия, шлуночкова тахікардія, aberrant conduction, 3. Good health, широкі комплекси QRS, supraventricular tachycardia, катетерна абляція, аберантное проведение, суправентрикулярная тахикардия, ventricular tachycardia, механізми, желудочковая тахикардия, антиаритмические препараты

File Description: application/pdf

Access URL: http://lu-journal.com.ua/article/view/271836

9

Academic Journal

Взаимосвязь уровней половых гормонов с развитием лекарственно-индуцированного удлинения интервала QT у женщин, принимающих антиаритмические препараты III класса ; Relationship of sex hormone levels with the development of drug-induced QT interval prolongation in women taking class III antiarrhythmic drugs

Authors: Kalatsei, L. V., Snezhitskiy, V. A., Колоцей, Л. В., Снежицкий, В. А.

Source: Сборник статей

Subject Terms: ESTRADIOL, PROGESTERONE, CLASS III ANTIARRHYTHMIC DRUGS, QT INTERVAL, POLYMORPHIC VENTRICULAR TACHYCARDIA, ЭСТРАДИОЛ, ПРОГЕСТЕРОН, АНТИАРИТМИЧЕСКИЕ ПРЕПАРАТЫ III КЛАССА, ИНТЕРВАЛ QT, ПОЛИМОРФНАЯ ЖЕЛУДОЧКОВАЯ ТАХИКАРДИЯ

File Description: application/pdf

Relation: Актуальные вопросы современной медицинской науки и здравоохранения: материалы VII Международной научно-практической конференции молодых учёных и студентов, Екатеринбург, 17-18 мая 2022 г.; http://elib.usma.ru/handle/usma/7497

Availability: http://elib.usma.ru/handle/usma/7497

View record from BASE

10

Academic Journal

Modern view on the etiopathogenesis of heart rhythm disorders and methods of their correction in pregnant women ; Современный взгляд на этиопатогенез нарушений ритма сердца у женщин в период беременности и методы их коррекции

Authors: R. Kh. Useinova, A. N. Sulima, A. N. Rybalka, D. A. Beglitse, Z. S. Rumyantseva, P. N. Baskakov, M. A. Dizha, E. M. Dolya, Р. Х. Усеинова, А. Н. Сулима, А. Н. Рыбалка, Д. A. Беглицэ, З. С. Румянцева, П. Н. Баскаков, М. А. Дижа, Е. М. Доля

Source: Obstetrics, Gynecology and Reproduction; Vol 15, No 4 (2021); 419-429 ; Акушерство, Гинекология и Репродукция; Vol 15, No 4 (2021); 419-429 ; 2500-3194 ; 2313-7347

Subject Terms: патогенез, arrhythmias in pregnacy, antiarrhythmic drugs, electro-pulse therapy, pregnancy, etiology, pathogenesis, аритмии во время беременности, антиаритмические препараты, электроимпульсная терапия, беременность, этиология

File Description: application/pdf

Relation: https://www.gynecology.su/jour/article/view/1070/934; Knotts R.J., Garan H. Cardiac arrhythmias in pregnancy. Semin Perinatol. 2014;38(5):285-8. https://doi.org/10.1053/j.semperi.2014.04.017.; Sanghavi M., Rutherford J.D. Cardiovascular physiology of pregnancy. Circulation. 2014;130:1003-8. https://doi.org/10.1161/CIRCULATIONAHA.114.009029.; Trappe H.-J. Cardiac arrhythmias in the pregnant woman and the foetus. European Cardiology. 2008;4(2):67-71. http://dx.doi.org/10.15420/ecr.2008.4.2.67.; Emmanuel Y., Thorne S.A. Heart disease in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2015; 29(5):579-97. https://doi.org/10.1016/j.bpobgyn.2015.04.002.; Абдрахманова А.И., Маянская С.Д, Средюк И.Л. Нарушение сердечного ритма у беременных. Практическая медицина. 2012;(9):45-51.; Silversides C.K., Grewal J., Mason J. et al. Pregnancy outcomes in women with heart disease: the CARPREG II study. J Am Coll Cardiol. 2018;71(21):2419-30. https://doi.org/10.1016/j.jacc.2018.02.076.; Schmidt C., Kisselbach J., Schweizer P.A. et al. The pathology and treatment of cardiac arrhythmias: focus on atrial fibrillation. Vasc Health Risk Manag. 2011;7:193-202. https://doi.org/10.2147/VHRM.S10758.; Gandhi M., Martin S.R. Cardiac disease in pregnancy. Obstet Gynecol Clin North Am. 2015;42(2):315-33. https://doi.org/10.1016/j.ogc.2015.01.012.; Bartos D.C., Grandi E., Ripplinger C.M. Ion channels in the heart. Compr Physiol. 2015;5(3):1423-64. https://doi.org/10.1002/cphy.c140069.; Sedmera D., Kockova R., Vostarek F., Raddatz E. Arrhythmias in the developing heart. Acta Physiol (Oxf). 2015;213(2):303-20. https://doi.org/10.1111/apha.12418.; Mendelsohn M.E., Karas R.H. Molecular and cellular basis of cardiovascular gender differences. Science. 2005;308(5728):1583-7. https://doi.org/10.1126/science.1112062.; Burke J., Goldberger J., Ehlert F.A. et al. Gender differences in heart rate before and after autonomic blockade: evidence against an intrinsic gender effect. Am J Med. 1996;100(5):537-43. https://doi.org/10.1016/s0002-9343(96)00018-6.; Ehdaie A., Cingolani E., Shehata M. et al. Sex differences in cardiac arrhythmias. Circ Arrhythm Electrophysiol. 2018;11(3):e005680. https://doi.org/10.1161/CIRCEP.117.005680.; Curtis A.B., Narasimha D. Arrhythmias in women. Clin Cardiol. 2012;35(3):166-71. https://doi.org/10.1002/clc.21975.; Magnani J.W., Moser C.B, Murabito J.M. et al. Association of sex hormones, aging, and atrial fibrillation in men: the Framingham Heart Study. Circ Arrhythm Electrophysiol. 2014;7(2):307-12. https://doi.org/10.1161/CIRCEP.113.001322.; Locati E.H., Zareba W., Moss A.J. et al. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. Circulation. 1998;97(22):2237-44. https://doi.org/10.1161/01.CIR.97.22.2237.; Gowd P., Thompson P.D. Effect of female sex on cardiac arrhythmias. Cardiol Rev. 2012;20(6):297-303. https://doi.org/10.1097/CRD.0b013e318259294b.; Nowak B., Misselwitz B., Expert committee 'Pacemaker', Institute of Quality Assurance Hessen et al. Do gender differences exist in pacemaker implantation? - results of an obligatory external quality control program. Europace. 2010; 12(2):250-5. https://doi.org/10.1093/europace/eup312.; Zylla M.M., Brachmann J., Lewalter T. et al. Sex-related outcome of atrial fibrillation ablation: insights from the German Ablation Registry. Heart Rhythm. 2016;13:1837-44. https://doi.org/10.1016/j.hrthm.2016.06.005; Westerman S., Wenger N. Gender differences in atrial fibrillation: a review of epidemiology, management, and outcomes. Curr Cardiol Rev. 2019;15(2):136-44. https://doi.org/10.2174/1573403X15666181205110624.; Burke J.H, Ehlert F.A., Kruse J.T. et al. Gender-specific differences in the QT interval and the effect of autonomic tone and menstrual cycle in healthy adults. Am J Cardiol. 1997;79(2):178-81. https://doi.org/10.1016/s0002-9149(96)00707-2.; Kurisu S., Kato Y., Mitsuba N. et al. Gender difference in QT interval in patients with primary aldosteronism. J Renin-Angiotensin-Aldosterone Syst. 2012;13(4):435-9. https://doi.org/10.1177/1470320312447651.; Ravens U. Sex differences in cardiac electrophysiology. Can J Physiol Pharmacol. 2018;96(10):985-90. https://doi.org/10.1139/cjpp-2018-0179.; Noyola-Martinez N., Halhali A., Barrera D. Steroid hormones and pregnancy. Gynecol Endocrinol. 2019;35(5):376-84. https://doi.org/10.1080/09513590.2018.1564742.; Kuijper E.A., Ket J.C., Caanen M.R., Lambalk C.B. Reproductive hormone concentrations in pregnancy and neonates: a systematic review. Reprod Biomed Online. 2013;27(1):33-63. https://doi.org/10.1016/j.rbmo.2013.03.009.; Adamson D.L., Nelson-Piercy C. Managing palpitations and arrhythmias during pregnancy. Heart. 2007;93(12):1630-6. https://doi.org/10.1136/hrt.2006.098822.; Silversides C.K., Harris L., Haberer K. et al. Recurrence rates of arrhythmias during pregnancy in women with previous tachyarrhythmia and impact on fetal and neonatal outcomes. Am J Cardiol. 2006;97:1206-12. https://doi.org/10.1016/j.amjcard.2005.11.041.; Nanda S., Nelson-Piercy C., Mackillop L. Cardiac disease in pregnancy. Clin Med (Lond). 2012;12(6):553-60. https://doi.org/10.7861/clinmedicine.12-6-553.; Afanasiuk O.I, Shmaliy V.I, Shushkovska Y.Y. Clinical characteristics of cardiac arrhythmias in pregnant women. Wiad Lek. 2019;72(3):381-83.; Enriquez A.D., Economy K.E., Tedrow U.B. Contemporary management of arrhythmias during pregnancy. Circ Arrhythm Electrophysiol. 2014;7(5):961-7. https://doi.org/10.1161/CIRCEP.114.001517.; Тереховская Ю.В., Смирнова Е.А. Нарушения ритма сердца у беременных. Наука молодых (Eruditio Juvenium). 2017;5(3):462-80. https://doi.org/10.23888/hmj20173462-480.; Wright J.M., Page R.L., Field M.E. Antiarrhythmic drugs in pregnancy. Expert Rev Cardiovasc Ther. 2015;13(12):1433-44. https://doi.org/10.1586/14779072.2015.1107476.; Roos-Hesselink J., Baris L., Johnson M. et al. Pregnancy outcomes in women with cardiovascular disease: evolving trends over 10 years in the ESC Registry Of Pregnancy And Cardiac disease (ROPAC). Eur Heart J. 2019;40(47):3848-55. https://doi.org/10.1093/eurheartj/ehz136.; Yaksh A., van der Does L.J., Lanters E.A., de Groot N.M. Pharmacological therapy of tachyarrhythmias during pregnancy. Arrhythm Electrophysiol Rev. 2016;5(1):41-4. https://doi.org/10.15420/AER.2016.1.2.; Regitz-Zagrosek V., Roos-Hesselink J.W., Bauersachs J. et al. 2018 ESC Guidelines on the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39:3165-241. https://doi.org/10.1093/eurheartj/ehy340.; Laksman Z., Harris L., Silversides C.K. Cardiac arrhythmias during pregnancy: a clinical approach. Fetal and Maternal Medicine Review. 2011;22(02):123-43. https://doi.org/10.1017/S0965539511000076.; Hsu J.C., Maddox T.M., Kennedy K. et al. Aspirin instead of oral anticoagulant prescription in atrial fibrillation patients at risk for stroke. J Am Coll Cardiol. 2016;67:2913-23. https://doi.org/10.1016/j.jacc.2016.03.581.; Chauveau S., Le Vavasseur O., Morel E. et al. Flecainide is a safe and effective treatment for pre-excited atrial fibrillation rapidly conducted to the ventricle in pregnant women: a case series. Eur Heart J Case Rep. 2019;3(2):ytz066. https://doi.org/10.1093/ehjcr/ytz066.; Goland S., Elkayam U. Anticoagulation in pregnancy. Cardiol Clin. 2012;30(3):395-405. https://doi.org/10.1016/j.ccl.2012.05.003.; Ferreira N.S., La Croix Barros T., Gismondi R.A. Supine frequent ventricular extrasystoles in a pregnant woman without structuralh Heart disease. Case Rep Med. 2016;2016:1-3. https://doi.org/10.1155/2016/6213198.; Wright J.M., Page R.L., Field M.E. Antiarrhythmic drugs in pregnancy. Expert Rev Cardiovasc Ther. 2015;13(12):1433-4. https://doi.org/10.1586/14779072.2015.1107476.; Gowda R.M., Khan I.A., Mehta N.J. et al. Cardiac arrhythmias in pregnancy: clinical and therapeutic considerations. Int J Cardiol. 2003;88(2-3):129-133. https://doi.org/10.1016/s0167-5273(02)00601-0.; Uzun O., Babaoglu K., Sinha A. et al. Rapid control of foetal supraventricular tachycardia with digoxin and flecainide combination treatment. Cardiol Young. 2012;22(4):372-80. https://doi.org/10.1017/S1047951111001272.; Trappe H.J. Emergency therapy of maternal and fetal arrhythmias during pregnancy. J Emerg Trauma Shock. 2010;3(2):153-9. https://doi.org/10.4103/0974-2700.62116.; https://www.gynecology.su/jour/article/view/1070

Availability: https://www.gynecology.su/jour/article/view/1070
https://doi.org/10.17749/2313-7347/ob.gyn.rep.2021.201

View record from BASE

11

Academic Journal

Supraventricular tachycardia: modern methods of diagnosis and treatment (мethodical recommendations)

Source: Лекарства Украины; № 7(253) (2021); 7-17
Medicine of Ukraine; No. 7(253) (2021); 7-17
Ліки України; № 7(253) (2021); 7-17

Subject Terms: рекомендации, supraventricular tachycardia, рекомендації, antiarrhythmic drugs, катетерна абляція, catheter ablation, recommendations, суправентрикулярная тахикардия, антиаритмічні препарати, антиаритмические препараты, катетерная абляция, 3. Good health, суправентрикулярна тахікардія

File Description: application/pdf

Access URL: http://lu-journal.com.ua/article/view/245641

12

Academic Journal

Влияние некоторых лекарственных препаратов различных фармакологических групп на вариабельность ритма сердца

Source: Качественная клиническая практика, Vol 0, Iss 1, Pp 100-105 (2018)

Subject Terms: вариабельность ритма сердца, бета-блокаторы, антиаритмические препараты, эстрогены, антагонисты кальция, ингибиторы апф, м-холинолитики, бета-адреномиметики, Medical technology, R855-855.5, Pharmacy and materia medica, RS1-441

File Description: electronic resource

Relation: https://www.clinvest.ru/jour/article/view/254; https://doaj.org/toc/2588-0519; https://doaj.org/toc/2618-8473

Access URL: https://doaj.org/article/296c578ea33c4d22ab1e3f95b9dc4d20

View record in DOAJ

13

Academic Journal

Influence of Some Antiarrhythmic Drugs on Uterine Tonus and Contraction (An Experimental Research)

Authors: A.Yu. Limanskaya

Source: Перинатологія і педіатрія; № 2(70) (2017): Перинатологія та педіатрія; 53-57
Перинатология и педиатрия; № 2(70) (2017): Перинатология и педиатрия; 53-57
Perinatologiya i pediatriya; № 2(70) (2017): Perinatologiya i pediatriya; 53-57

Subject Terms: тонус и сократительная деятельность матки, антиаритмические препараты, uterine tonus and contraction, antiarrhythmic drugs, тонус і скоротлива діяльність матки, антиаритмічні препарати, 3. Good health

File Description: application/pdf

Access URL: http://pip.med-expert.com.ua/article/view/PP.2017.70.53

View record at OpenAIRE Full Text Finder

14

Academic Journal

Drug-Induced Heart Failure (Part 1: The Urgency of the Problem, the Prevalence, the Effect of Certain Groups of Drugs on the Risk of Development/Progression Heart Failure) ; Лекарственно-индуцированная сердечная недостаточность (часть 1: актуальность, распространенность, причины)

Authors: O. D. Ostroumova, I. V. Goloborodova, О. Д. Остроумова, И. В. Голобородова

Contributors: Работа выполнена без спонсорской поддержки.

Source: Safety and Risk of Pharmacotherapy; Том 8, № 1 (2020); 23-35 ; Безопасность и риск фармакотерапии; Том 8, № 1 (2020); 23-35 ; 2619-1164 ; 2312-7821 ; 10.30895/2312-7821-2020-8-1

Subject Terms: нестероидные противовоспалительные средства, drug-induced heart failure, calcium channel blockers, beta-blockers, antiarrhythmics, hypoglycemic drugs, anthracyclines, anticancer drugs, non-steroidal anti-inﬂ ammatory drugs, лекарственно-индуцированная сердечная недостаточность, блокаторы кальциевых каналов, бета-блокаторы, антиаритмические препараты, гипогликемические препараты, антрациклины, противоопухолевые средства

File Description: application/pdf

Relation: https://www.risksafety.ru/jour/article/view/171/231; Мареев ВЮ, Фомин ИВ, Агеев ФТ, Беграмбекова ЮЛ, Васюк ЮА, Гарганеева АА и др. Клинические рекомендации ОССН — РКО — РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018;58(6S):8–158.; Гарганеева АА, Бауэр ВА, Борель КН. Пандемия XXI века: хроническая сердечная недостаточность — бремя современного общества. Эпидемиологические аспекты (обзор литературы). Сибирский медицинский журнал. 2014;29(3):8–12.; Page RL 2nd, O’Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, et al. Drugs that may cause or exacerbate heart failure: a scientiﬁ c statement from the American Heart Association. Circulation. 2016;134(6):е32–69. https://doi.org/10.1161/CIR.0000000000000426; Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200. https://doi.org/10.1093/eurheartj/ehw128; Al Hamarneh YN, Tsuyuki RT. Heart failure. In: Tisdale JE, Miller DA, eds. Drug-induced diseases: prevention, detection, and management. 3rd ed. Bethesda: American Society of Health-System Pharmacists; 2018. Р. 501–21.; DeFrances CJ, Cullen KA, Kozak LJ. National Hospital Discharge Survey: 2005 annual summary with detailed diagnosis and procedure data. Vital Health Stat. 2007;13(165).; Беленков ЮН, Мереев ВЮ, Агеев ФТ, Фомин ИВ, Бадин ЮВ, Поляков ДС и др. Современный образ пациента с ХСН в европейской части Российской Федерации (госпитальный этап). Сердечная недостаточность. 2011;12(5):255–9.; Ситникова МЮ, Лясникова ЕА, Трукшина МА. Хроническая сердечная недостаточность: эпидемиология и перспективы планирования. Журнал Сердечная недостаточность. 2012;13(6):372–6.; Напалков ДА, Сулимов ВА, Сеидов НМ. Хроническая сердечная недостаточность: смещение фокуса на начальные стадии заболевания. Лечащий врач. 2008;8(4):58–60; Parkes JD, Marsden CD, Price P. Amantadine-induced heartfailure. Lancet. 1977;309(8017):904. https://doi.org/10.1016/s0140-6736(77)91226-0; Maxwell CB, Jenkins АT. Drug-induced heart failure. Am J Health Syst Pharm. 2011;68(19):1791–804. https://doi.org/10.2146/ajhp100637; Tang WH, Francis GS, Hoogwerf BJ, Young JB. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol. 2003;41(8):1394–8. https://doi.org/10.1016/S0735-1097(03)00159-1; Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427– 43. https://doi.org/10.1056/NEJMoa066224; The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet. 2006;368(9541):1096–105. https://doi.org/10.1016/S0140-6736(06)69420-8; Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, et al. Rosiglitazone evaluated for cardiovascular outcomes — an interim analysis. N Engl J Med. 2007;357(1):28–38. https://doi.org/10.1056/NEJMoa073394; Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–89. https://doi.org/10.1016/s0140-6736(05)67528-9; Hernandez AV, Usmani A, Rajamanickam A, Moheet A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs. 2011;11(2):115–28. https://doi.org/10.2165/11587580-000000000-00000; Filion KB, Joseph L, Boivin JF, Suissa S, Brophy JM. Thiazolidinediones and the risk of incident congestive heart failure among patients with type 2 diabetes mellitus. Pharmacoepidemiol Drug Saf. 2011;20(8):785–96. https://doi.org/10.1002/pds.2165; Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ. 2011;342:d1309. https://doi.org/10.1136/bmj.d1309; Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomized clinical trials. Lancet. 2007;370(9593):1129–36. https://doi.org/10.1016/S0140-6736(07)61514-1; Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010;304(4):411– 8. https://doi.org/10.1001/jama.2010.920; Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130(18):1579–88. https://doi.org/10.1161/circulationaha.114.010389; White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35. https://doi.org/10.1056/NEJMoa1305889; Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–42. https://doi.org/10.1056/NEJMoa1501352; Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91(5):710– 7. https://doi.org/10.7326/0003-4819-91-5-710; Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869–79. https://doi.org/10.1002/cncr.11407; Kremer LC, van Dalen EC, Offringa M, Voûte PA, et al. Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann Oncol. 2002;13(4):503–12. https://doi.org/10.1093/annonc/mdf118; Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92. https://doi.org/10.1056/NEJM200103153441101; Ewer SM, Ewer MS. Cardiotoxicity proﬁle of trastuzumab. Drug Saf. 2008;31(6):459–67. https://doi.org/10.2165/00002018200831060-00002; Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–84. https://doi.org/10.1056/NEJMoa052122; Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, et al. Trastuzumab-assоciated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007;25(25):3859–65. https://doi.org/10.1200/JCO.2006.09.1611; Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005;23(31):7811–9. https://doi.org/10.1200/JCO.2005.02.4091; Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–72. https://doi.org/10.1056/NEJMoa052306; Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354(8):809–20. https://doi.org/10.1056/NEJMoa053028; Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215–21. https://doi.org/10.1200/JCO.2002.20.5.1215; Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol. 2006;24(25):4107–15. https://doi.org/10.1200/JCO.2005.04.9551; Choueiri TK, Mayer EL, Je Y, Rosenberg JE, Nguyen PL, Azzi GR, et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol. 2011;29(6):632– 8. https://doi.org/10.1200/JCO.2010.31.9129; Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of inﬂ iximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107(25):3133–40. https://doi.org/10.1161/01.CIR.0000077913.60364.D2; Ravid S, Podrid PJ, Lampert S, Lown B. Congestive heart failure induced by six of the newer antiarrhythmic drugs. J Am Coll Cardiol. 1989;14(5):1326–30. https://doi.org/10.1016/0735-1097(89)90436-1; Greene HL, Richardson DW, Hallstrom AP, McBride R, Capone RJ, Barker AH, et al. Congestive heart failure after acute myocardial infarction in patients receiving antiarrhythmic agents for ventricular premature complexes (Cardiac Arrhythmia Pilot Study). Am J Cardiol. 1989;63(7):393–8. https://doi.org/10.1016/0002-9149(89)90306-8; Pﬁ sterer M. Negative inotropic effects of antiarrhythmic drugs: a clinical point of view. J Cardiovasc Pharmacol. 1991;17(Suppl 6):S44–7.; Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2016;68(13):1476–88. https://doi.org/10.1016/j.jacc.2016.05.011; Køber L, Torp-Pedersen C, McMurray JJ, Gøtzsche O, Lévy S, Crĳ ns H, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358(25):2678–87. https://doi.org/10.1056/NEJMoa0800456; Hohnloser SH, Crĳ ns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, et al. Effect of dronedarone on cardiovascular events in atrial ﬁbrillation. N Engl J Med. 2009;360(7):668–78. https://doi.org/10.1056/NEJMoa0803778; Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial ﬁbrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962. https://doi.org/10.1093/eurheartj/ehw210; The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988;319(7):385–92. https://doi.org/10.1056/NEJM198808183190701; Moss AJ, Oakes D, Benhorin J, Carleen E. The interaction between diltiazem and left ventricular function after myocardial infarction. Multicenter Diltiazem Post-Infarction Research Group. Circulation. 1989;80(Suppl 6):IV102–6.; Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation. 1991;83(1):52–60. https://doi.org/10.1161/01.cir.83.1.52; Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola SH. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation. 1990;82(6):1954–61. https://doi.org/10.1161/01.cir.82.6.1954; Packer M, Carson P, Elkayam U, Konstam MA, Moe G, O’Connor C, et al. Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (Prospective Randomized Amlodipine Survival Evaluation 2). JACC Heart Fail. 2013;1(4):308–14. https://doi.org/10.1016/j.jchf.2013.04.004; Greenblatt DJ, Koch-Weser J. Adverse reactions to β-adrenergic receptor blocking drugs: a report from the Boston collaborative drug surveillance program. Drugs. 1974;7(1-2):118–29. https://doi.org/10.2165/00003495-197407010-00008; McKelvie RS, Moe GW, Ezekowitz JA, Heckman GA, Costigan J, Ducharme A, et al. The 2012 Canadian Cariovascular Society heart failure management guideline update: focus on acute and chronic heart failure. Can J Cardiol. 2013;29(2):168–81. https://doi.org/10.1016/j.cjca.2012.10.007; Tsuyuki RT, McAlister FA, Teo KK. β-blockers for congestive heart failure: what is the current consensus? Drugs Aging. 2000;16(1):1–7. https://doi.org/10.2165/00002512-200016010-00001; Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Clinical effects of β-adrenergic blockade in chronic heart failure: a metaanalysis of double-blind, placebo-controlled, randomized trials. Circulation. 1998;98(12):1184–91. https://doi.org/10.1161/01.cir.98.12.1184; Avezum A, Tsuyuki RT, Pogue J, Yusuf S. Beta-blocker therapy for congestive heart failure: a systemic overview and critical appraisal of the published trials. Can J Cardiol. 1998;14(8):1045–53.; Ko DT, Hebert PR, Coffey CS, Curtis JP, Foody JM, Sedrakyan A, Krumholz HM. Adverse effects of β-blocker therapy for patients with heart failure: a quantitative overview of randomized trials. Arch Intern Med. 2004;164(13):1389–94. https://doi.org/10.1001/archinte.164.13.1389; Everitt DE, Avorn J. Systemic effects of medications used to treat glaucoma. Ann Intern Med. 1990;112(2):120–5. https://doi.org/10.7326/0003-4819-112-2-120; Munroe WP, Rindone JP, Kershner RM. Systemic side effects associated with the ophthalmic administration of timolol. Drug Intell Clin Pharm. 1985;19(2):85–9. https://doi.org/10.1177/106002808501900201; Heerdink ER, Leufkens HG, Herings RM, Ottervanger JP, Stricker BH, Bakker A. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med. 1998;158(10):1108–12. https://doi.org/10.1001/archinte.158.10.1108; Bleumink GS, Feenstra J, Sturkenboom MC, Stricker BH. Nonsteroidal anti-inﬂ ammatory drugs and heart failure. Drugs. 2003;63(6):525–34. https://doi.org/10.2165/00003495200363060-00001; Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC. Cost of heart failure among hypertensive users of nonspeciﬁ c NSAIDs and COX-2-speciﬁc inhibitors. Am J Manag Care. 2002;8(15 Suppl):S414–27.; Whelton A, White WB, Bello AE, Puma JA, Fort JG, SUCCESS-VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol. 2002;90(9):959–63. https://doi.org/10.1016/s0002-9149(02)02661-9; Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inﬂ ammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet. 2004;363(9423):1751–6. https://doi.org/10.1016/S0140-6736(04)16299-5; Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Fosbøl EL, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal antiinﬂ ammatory drugs in chronic heart failure. Arch Intern Med. 2009;169(2):141–9. https://doi.org/10.1001/archinternmed.2008.525; https://www.risksafety.ru/jour/article/view/171

Availability: https://www.risksafety.ru/jour/article/view/171
https://doi.org/10.30895/2312-7821-2020-8-1-23-35

View record from BASE

15

Academic Journal

Drug-Induced Heart Failure (Part 2: Mechanisms of Development, Clinical Signs, Differential Diagnosis, Risk Factors, Treatment and Prevention) ; Лекарственно-индуцированная сердечная недостаточность (часть 2: механизмы развития, клиническая картина, дифференциальная диагностика, факторы риска, лечение и профилактика)

Authors: O. D. Ostroumova, I. V. Goloborodova, О. Д. Остроумова, И. В. Голобородова

Contributors: The study was performed without external funding.

Source: Safety and Risk of Pharmacotherapy; Том 8, № 2 (2020); 57-65 ; Безопасность и риск фармакотерапии; Том 8, № 2 (2020); 57-65 ; 2619-1164 ; 2312-7821 ; 10.30895/2312-7821-2020-8-2

Subject Terms: нестероидные противовоспалительные средства, drug-induced heart failure, pathogenesis, risk factors, calcium channel blockers, beta-blockers, antiarrhythmic drugs, anthracyclines, hypoglycemic drugs, glitazones, nonsteroidal anti-inflammatory drugs, лекарственно-индуцированная сердечная недостаточность, патогенез, факторы риска, блокаторы кальциевых каналов, бета-адреноблокаторы, антиаритмические препараты, антрациклины, гипогликемические препараты, глитазоны

File Description: application/pdf

Relation: https://www.risksafety.ru/jour/article/view/172/251; Page RL 2nd, O’Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation. 2016;134(6):е32–69. https://doi.org/10.1161/CIR.0000000000000426; Al Hamarneh YN, Tsuyuki RT. Heart failure. In: Tisdale JE, Miller DA, eds. Drug-induced diseases: prevention, detection, and management. 3rd ed. Bethesda: American Society of Health-System Pharmacists; 2018. Р. 501–21.; Остроумова ОД, Голобородова ИВ. Лекарственно-индуцированная сердечная недостаточность (часть 1: актуальность, распространенность, причины). Безопасность и риск фармакотерапии. 2020;8(1):23–35. https://doi.org/10.30895/2312-7821-2020-8-1-23-35; Parameshwar J, Poole-Wilson PA. The role of calcium antagonists in the treatment of chronic heart failure. Eur Heart J. 1993;14(Suppl A):38–44. https://doi.org/10.1093/eurheartj/14.suppl_a.38; Dougall HT, McLay J. A comparative review of the adverse effects of calcium antagonists. Drug Saf. 1996;15(2):91–106. https://doi.org/10.2165/00002018-199615020-00002; Bohm M, Schwinger RH, Erdmann E. Different cardiodepressant potency of various calcium antagonists in human myocardium. Am J Cardiol. 1990;65(15):1039–41. https://doi.org/10.1016/0002-9149(90)91013-v; Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola SH. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation. 1990;82(6):1954–61. https://doi.org/10.1161/01.cir.82.6.1954; Packer M, Carson P, Elkayam U, Konstam MA, Moe G, O’Connor C, et al. Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2). JACC Heart Fail. 2013;1(4):308–14. https://doi.org/10.1016/j.jchf.2013.04.004; Cohn JN, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation. 1997;96(3):856–63. https://doi.org/10.1161/01.CIR.96.3.856; Podrid PJ. Safety and toxicity of antiarrhythmic drug therapy: benefit versus risk. J Cardiovasc Pharmacol. 1991;17(Suppl 6):S65–73.; Pfisterer M. Negative inotropic effects of antiarrhythmic drugs: a clinical point of view. J Cardiovasc Pharmacol. 1991;17(Suppl 6):S44–7.; Frishman WH, Sung HM, Yee HC, Liu LL, Keefe D, Einzig AI, et al. Cardiovascular toxicity with cancer chemotherapy. Curr Probl Cancer. 1997;21(6):301–60. https://doi.org/10.1016/s0147-0272(97)80001-3; Porembka DT, Lowder JN, Orlowski JP, Bastulli J, Lockrem J. Etiology and management of doxorubicin cardiotoxicity. Crit Care Med. 1989;17(6):569–72. https://doi.org/10.1097/00003246-198906000-00019; Кузьмина ТП, Давыдкин ИЛ, Терешина ОВ, Данилова ОЕ, Шпигель АС, Бетанели ТШ и др. Кардиотоксичность и методы ее диагностики у пациентов гематологического профиля (обзор литературы). Сибирский научный медицинский журнал. 2019;39(1):34–42. https://doi.org/10.15372/SSMJ20190105; Saini J, Rich MW, Lyss AP. Reversibility of severe left ventricular dysfunction due to doxorubicin cardiotoxicity: report of three cases. Ann Intern Med. 1987;106(6):814–6. https://doi.org/10.7326/0003-4819-106-6-814; Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crĳ ns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012;52(6):1213–25. https://doi.org/10.1016/j.yjmcc.2012.03.006; Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005;23(13):2900–2. https://doi.org/10.1200/JCO.2005.05.827; Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23(31):7820–6. https://doi.org/10.1200/JCO.2005.13.300; Степанова ЕВ, Зейналова КР. Механизмы резистентности к трастузумабу. Российский биотерапевтический журнал. 2011;10(3):3–8.; Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Saf. 2008;31(6):459–67. https://doi.org/10.2165/00002018-200831060-00002; Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumabrelated cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol. 2007;25(23):3525–33. https://doi.org/10.1200/JCO.2007.11.0106; Choueiri TK, Mayer EL, Je Y, Rosenberg JE, Nguyen PL, Azzi GR, et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol. 2011;29(6):632–8. https://doi.org/10.1200/JCO.2010.31.9129; Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003; 107(25):3133–40. https://doi.org/10.1161/01.CIR.0000077913.60364.D2; Maxwell CB, Jenkins AT. Drug-induced heart failure. Am J Health Syst Pharm. 2011;68(19):1791–804. https://doi.org/10.2146/ajhp100637; Tang WH, Francis GS, Hoogwerf BJ, Young JB. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol. 2003;41(8):1394–8. https://doi.org/10.1016/S0735-1097(03)00159-1; Mudaliar S, Henry RR. New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers. Annu Rev Med. 2001;52:239–57. https://doi.org/10.1146/annurev.med.52.1.239; Wooltorton E. Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure. CMAJ. 2002;166(2):219.; Karalliedde J, Buckingham R, Starkie M, Lorand D, Stewart M, Viberti G, et al. Effect of various diuretic treatments on rosiglitazone-induced fluid retention. J Am Soc Nephrol. 2006;17(12):3482–90. https://doi.org/10.1681/ASN.2006060606; Karalliedde J, Buckingham RE. Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies. Drug Saf. 2007;30(9):741–53. https://doi.org/10.2165/00002018-200730090-00002; Bleumink GS, Feenstra J, Sturkenboom MC, Stricker BH. Nonsteroidal anti-inflammatory drugs and heart failure. Drugs. 2003;63(6):525–34. https://doi.org/10.2165/00003495-200363060-00001; Feenstra J, Grobbee DE, Mosterd A, Stricker BH. Adverse cardiovascular effects of NSAIDs in patients with congestive heart failure. Drag Saf. 1997;17(3):166–80. https://doi.org/10.2165/00002018-199717030-00003; Леонова МВ, Алимова ЭЭ, Еремина ЮН. Опасная комбинация ингибиторов ангиотензинпревращающего фермента, диуретиков и нестероидных противовоспалительных средств в клинической практике. Фарматека. 2016;(19):69–75.; Nurmohamed MT, van Halm VP, Dĳkmans BA. Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis. Drugs. 2002;62(11):1599–609. https://doi.org/10.2165/00003495-200262110-00003; Мареев ВЮ, Фомин ИВ, Агеев ФТ, Беграмбекова ЮЛ, Васюк ЮА, Гарганеева АА и др. Клинические рекомендации ОССН — РКО — РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018;58(S6):8–158. https://doi.org/10.18087/cardio.2475; Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200. https://doi.org/10.1093/eurheartj/ehw128; Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91(5):710–7. https://doi.org/10.7326/0003-4819-91-5-710; Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2004;27(1):56–63. https://doi.org/10.2337/diacare.27.1.256; Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130(18):1579–88. https://doi.org/10.1161/CIRCULATIONAHA.114.010389; White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35. https://doi.org/10.1056/NEJMoa1305889; Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–42. https://doi.org/10.1056/NEJMoa1501352; Чернов ВИ, Кравчук ТЛ, Зельчан РВ, Подоплекин ДМ, Гольдберг ВЕ. Возможности медикаментозной профилактики антрациклин-индуцированной кардиотоксичности. Сибирский онкологический журнал. 2015;1(1):19–25.; Евсина ОВ, Селиверстова ДВ. Подходы к профилактике кардиотоксичности у пациентов с онкологической патологией. Кардиология. 2018;58(S11):4–13. https://doi.org/10.18087/cardio.2514; Дедов ИИ, Шестакова МВ, Майоров АЮ, ред. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 9-й выпуск. Сахарный диабет. 2019;22(S1):1–144. https://doi.org/10.14341/DM221S1; Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70(6):776–803. https://doi.org/10.1016/j.jacc.2017.04.025; Arnold JM, Howlett JG, Dorian P, Ducharme A, Giannetti N, Haddad H, et al. Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Can J Cardiol. 2007;23(1):21–45. https://doi.org/10.1016/s0828-282x(07)70211-8; https://www.risksafety.ru/jour/article/view/172